Meral Beksaç - Concepedia

Author

Meral Beksaç

Also Known As

B. Meral, Bart Barlogie, Beksac Meral, Beksac, Meral, Brian C.-H. Chiu, Buket Meral, Florida Bazarbachi, M Beksac, M Beksaç, M. Beksac

284

Publications

16.5K

Citations

H-Index

Concepts

All Affiliations

Ankara University National and Kapodistrian University of Athens Dana-Farber Cancer Institute Emory University Instituto de Investigación Biomédica de Salamanca

About

Meral Beksaç is an author at Ankara University specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	45	8K
2	Health Sciences	15	19	1.8K
3	Education	1	1	61
4	Engineering	1	1	71
5	Nursing	1	1	61

Meral Beksaç

Publications

12.6K

Citations

H-Index

Page 1

	Year	Citations
International uniform response criteria for multiple myeloma Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel, Leukemia Hematological MalignancyOncologyMalignant Blood DisorderHematologyMultiple Myeloma	2006	2.6K
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel, New England Journal of Medicine	2016	1.5K
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma Sagar Lonial, Meletios Α. Dimopoulos, Antonio Palumbo, New England Journal of Medicine	2015	1.3K
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon, The Lancet Oncology Hematological MalignancyDouble-blind Phase 3MedicineDexamethasone Versus PlaceboHematology	2014	781
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study Michel Attal, Paul G. Richardson, S. Vincent Rajkumar, The Lancet Hematological MalignancyMedicineImmunologyHematologyPharmacotherapy	2019	620
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis Efstathios Kastritis, Giovanni Palladini, Monique C. Minnema, New England Journal of Medicine	2021	609
The Shaping of Modern Human Immune Systems by Multiregional Admixture with Archaic Humans Laurent Abi‐Rached, Matthew J. Jobin, Subhash Kulkarni, Science HistocompatibilityArchaic AllelesAdaptive Immune SystemGeneticsArtificial Immune System	2011	550
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders Andy C. Rawstron, Alberto Órfão, Meral Beksaç, Haematologica ImmunohematologyImmunologyPathologyImmunophenotypingPlasma Cells	2008	508
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study Michèle Cavo, Francesca Gay, Meral Beksaç, The Lancet Haematology Hematological MalignancyTransplantationMarrow TransplantationMedicineStem Cell Transplantation	2020	377
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro, The Lancet Oncology Hematological MalignancyOncologyDexamethasone Versus PomalidomideMetronomic TherapyImmunology	2021	316

Page 1